Cognito Therapeutics announced a collaboration with Ochsner Health to pilot its investigational Spectris non-invasive neuromodulation system across Ochsner’s clinical network in the Gulf South.
This is Cognito’s second major clinical partnership. The company launched a “Brain Health Collaboratory” with West Virginia University Rockefeller Neuroscience Institute last fall, and said the new agreement with Ochsner expands that effort into Louisiana, Mississippi and neighboring areas.
Spectris delivers proprietary gamma-frequency light and sound stimulation intended to evoke EEG‑confirmed gamma oscillations, the company said. Cognito described the platform as investigational and designed to restore brain electrical activity that is disrupted in Alzheimer’s disease.
Collaboration goals and data plans
Cognito and Ochsner plan to build a regional platform for non-invasive brain health care and to develop a Brain Health Index to track cognitive status, disease progression and treatment response in real-world settings. The partners said they will explore integrating Spectris into clinical care pathways, including programs that serve dual-eligible Medicare and Medicaid patients.
The companies also said they aim to generate clinical and health-economics data to assess cost-effectiveness and Spectris’ role within value-based care models. Cognito framed the Ochsner network as a way to collect broader real-world evidence beyond major academic centers.
"Ochsner’s reach across the Gulf South provides a unique opportunity to bring innovative brain health technologies to a broad patient population," Cognito CEO Christian Howell said in the company release. "Expanding access to patients is critical to generating real-world evidence and ultimately delivering new options for people living with Alzheimer’s disease."
Dr. David Houghton, system chair of neurology at Ochsner Health, said the partnership will pair "emerging neurotechnology with real-world clinical care to better understand how we can slow cognitive decline, improve patients’ lives and open new therapeutic pathways."
Ochsner noted its neuroscience programs will consolidate at a new 132,000-square-foot Patrick Neuroscience Institute in New Orleans, scheduled to open in late 2026, which the partners said will support the collaboration.
Photo credit: wtwh-marketing.s3.amazonaws.com
Tags: Cognito Therapeutics, Spectris, Ochsner Health, gamma entrainment, Alzheimer's disease
Topics: Neurotech industry & startups, Non-invasive brain stimulation, Neuromodulation